<DOC>
	<DOCNO>NCT02606305</DOCNO>
	<brief_summary>This phase 1b study ass safety , tolerability , preliminary anti-tumor activity IMGN853 administer chemotherapy . Patients assign one four regimen : IMGN853 administer bevacizumab , IMGN853 administer carboplatin , IMGN853 administer pegylated liposomal doxorubicin IMGN853 administer pembrolizumab .</brief_summary>
	<brief_title>Study Mirvetuximab Soravtansine Comb . With Bevacizumab , Carboplatin , PLD Pembrolizumab Adults With FRa + Adv . EOC , Primary Peritoneal , Fallopian Tube , Endometrial Cancer</brief_title>
	<detailed_description>The dose escalation part study ass safety tolerability determine maximum tolerate dose ( MTD ) regimen . The dose expansion MTD ass safety , tolerability preliminary anti-tumor activity .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosed advanced epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer , endometrial cancer Folate receptor alpha positive tumor expression define protocol Willing undergo tumor biopsy Primary platinum refractory Diagnosis clear cell low grade ovarian cancer Serious concurrent illness clinically relevant active infection , include know diagnosis HIV hepatitis B C , define protocol Active autoimmune disease require systemic therapy past 2 year ( IMGN853 pembrolizumab ) Women pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Epithelial ovarian cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>Endometrial cancer</keyword>
	<keyword>IMGN853</keyword>
	<keyword>ADC</keyword>
	<keyword>Antibody drug conjugate</keyword>
	<keyword>ImmunoGen</keyword>
	<keyword>Antibody</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Folate receptor alpha</keyword>
</DOC>